Analysts Offer Predictions for ARCT FY2026 Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Arcturus Therapeutics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the biotechnology company will post earnings of ($3.06) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.22) per share.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($1.58) by $1.06. The business had revenue of $29.38 million for the quarter, compared to analyst estimates of $25.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%.

A number of other equities analysts have also weighed in on the stock. Wall Street Zen raised shares of Arcturus Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Wells Fargo & Company reduced their target price on shares of Arcturus Therapeutics from $50.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, May 14th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Arcturus Therapeutics in a research note on Thursday, April 10th. Scotiabank started coverage on shares of Arcturus Therapeutics in a research note on Wednesday, May 28th. They issued a “sector outperform” rating and a $32.00 target price for the company. Finally, BTIG Research set a $48.00 target price on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $53.50.

Arcturus Therapeutics Trading Up 2.9%

Shares of NASDAQ ARCT opened at $12.90 on Tuesday. The firm has a market cap of $349.86 million, a PE ratio of -5.81 and a beta of 2.30. Arcturus Therapeutics has a 1-year low of $8.04 and a 1-year high of $34.17. The company has a fifty day moving average price of $11.55 and a 200 day moving average price of $14.53.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Strs Ohio bought a new position in Arcturus Therapeutics in the first quarter valued at approximately $89,000. Acadian Asset Management LLC bought a new stake in shares of Arcturus Therapeutics in the 1st quarter valued at about $701,000. Goldman Sachs Group Inc. raised its holdings in shares of Arcturus Therapeutics by 9.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company’s stock valued at $5,398,000 after purchasing an additional 42,636 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Arcturus Therapeutics in the 1st quarter valued at about $299,000. Finally, Millennium Management LLC bought a new stake in shares of Arcturus Therapeutics in the 1st quarter valued at about $4,892,000. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.